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Summary 
BACKGROUND AND PURPOSE. Shiga toxin-producing Escherichia coli (STEC) 
infections could be one of the causes of fetal morbimortality in pregnant women. We 
have previously reported that Shiga toxin type 2 (Stx2) causes preterm delivery in 
pregnant rats. In this study, we evaluate the role of tumor necrosis factor alpha (TNF-α), 
prostaglandins (PGs), and nitric oxide (NO) in the Stx2induced preterm delivery.  
EXPERIMENTAL APPROACH. Pregnant rats were treated with 0.7 ng Stx2/g of body 
weight and killed at different times after treatment. Placenta and decidua were used to 
analyze NO synthase (NOS) activity by conversion L-[14C]arginine into L-[14C]citruline, 
PGE2 and PGF2α by radioimmunoassay, and cyclooxygenases (COX) protein by 
Western blot. TNF-α level was analyzed in serum by ELISA and by L929 cytotoxicity. 
Aminoguanidine (AG, inducible NOS inhibitor), meloxicam (Melo, COX-2 inhibitor) and 
etanercept (ETA, competitive inhibitor of TNF-α) were used alone or combined to inhibit 
NO, PGs and TNF-α production respectively, to prevent Stx2-induced preterm delivery.  
KEY RESULTS. Stx2 increased placental PGE2 and decidual PGF2α levels as well as 
COX-2 expression in both tissues. AG and Melo delayed the preterm delivery time but 
did not prevent it. ETA blocked the TNF-α increase after Stx2 treatment and reduced 
the preterm delivery by approximately 30%. The combined action of AG and ETA 
prevented Stx2-induced preterm delivery by roughly 70 %.  
CONCLUSIONS AND IMPLICATIONS. Our results demonstrate for the first time that 
the increase of TNF-α and NO produced by Stx2 are mostly responsible for the preterm 
delivery in rats.  
Key words: Preterm delivery, Stx2 treatment, Nitric oxide, Prostaglandins, Tumor 
necrosis factor-alpha, Pregnant rats, Cyclooxygenases, nitric oxide synthase A
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List of abbreviations:  
AG: aminoguanidine 
ANOVA: analysis of variance 
bwt: body weight 
Cyclooxygenases: COX 
ETA: etanercept 
Gb3: globotriaosylceramide 
gd: gestation day 
HUS: hemolytic uremic syndrome 
IL: interleukins 
iNOS: inducible NO synthase 
i.p.: intraperitoneal 
LB: Luria Broth  
LPS: lipopolysaccharide 
Melo: meloxicam 
NO: nitric oxide 
NOS: NO synthase 
PBS: phosphate buffer solution A
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PGs: prostaglandins 
PGE2: PGE-2 
PGF2α: PGF-2α 
PVDF: polyvinylidene difluoride 
SEM: Standard error of measurement 
STEC: Shiga toxin-producing Escherichia coli 
Stx: Shiga toxin 
Stx2: Shiga toxin type 2  
TNF-α: tumor necrosis factor alpha 
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Introduction 
Gastrointestinal infection with Shiga toxin (Stx)-producing E. coli (STEC) strains causes 
diarrhea and hemorrhagic colitis and, in addition, it is the leading cause of hemolytic 
uremic syndrome (HUS) (Richardson et al., 1988). HUS is characterized by a triad of 
hemolytic anemia, thrombocytopenia, and acute renal failure (Gianantonio et al., 1964; 
Repetto, 1997).  
HUS is most commonly seen in young children but it is occasionally present in adults 
(Scully et al., 1995; Repetto, 1997; Frank et al., 2011), including post-partum women. 
The most postpartum cases had preceeded upper respiratory or gastrointestinal 
symptoms (Strauss et al., 1976; Steele et al., 1984) and at least in one case, HUS was 
detected after a preterm delivery at 32 weeks (Steele et al., 1984). However, to our 
knowledge, an increased risk of preterm delivery linked to STEC infection has not yet 
been evaluated.  
HUS is a systemic complication attributed to the expression of Stx (Karmali et al., 
1983). Two types of Stx may be produced by STEC strains: Stx1 and/or Stx2 with their 
variants (Paton and Paton, 1998). In Argentina, STEC strain O157:H7 producing only 
Stx2 is highly prevalent (Rivas et al., 2006). Stx is an AB5 holotoxin possessing a single 
A subunit in noncovalent association with five B subunits (Fraser et al., 1994). The B 
subunits form a pentameric ring and mediate toxin binding to the glycolipid receptor 
globotriaosylceramide (Gb3) expressed in vascular endothelial cells, podocytes, 
mesangial cells, and proximal tubule epithelial cells of the kidney (Lingwood et al., 
1987; Lingwood, 1996). The A-subunit is an N-glycosidase, which removes an adenine 
of the 28S ribosomal RNA resulting in cell death (Endo et al., 1988).  
We have previously reported that intraperitoneal (i.p.) administration of Stx2 in the late 
stage of pregnancy produces preterm delivery of dead fetuses (Burdet et al., 2009). An A
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overproduction of nitric oxide (NO) and damage in placenta prevented by 
aminoguanidine (AG), an inducible NO synthase (iNOS) inhibitor, demonstrated that NO 
plays an important role in placental toxicity and fetal mortality induced by Stx2 (Burdet 
et al., 2010).  
During inflammation, prostaglandins (PGs) are released simultaneously with NO and 
their overproduction could be detrimental. PGs promote uterine contractions 
contributing to embryonic expulsion (Aisemberg et al., 2007). Stx may act in concert 
with bacterial lipopolysaccharide (LPS) and induce the production of tumor necrosis 
factor alpha (TNF-α) and interleukins (IL) as IL-1 and IL-6 by macrophages rendering 
the vascular endothelial cells more sensitive to the toxin (Tesh et al., 1994; Louise et 
al., 1991). Furthermore, high concentrations of many cytokines in the vaginal or cervical 
secretions including TNF-α and IL-6 in women with symptoms of preterm labor are 
associated with early preterm delivery (Inglis et al., 1994). 
These observations led us to investigate whether PGs and TNF-α could be involved in 
Stx2-induced preterm delivery in rats.  
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Materials and Methods 
Drugs and Chemicals 
L-[
14
C]Arginine (specific activity 360 mCi/mmol), [5,6,8,11,12,14,15-3H(N)]-PGE2 
(specific activity 150 Ci/mmol), and [5,6,8,9,11,12,14,15-3H(N)]- PGF2α (specific activity 
200 Ci/mmol) were from Perkin Elmer Life and Analytical Sciences, USA. ECL detection 
system, Biotrak rat TNF-α ELISA and actinomycin D were from GE Healthcare Life 
Sciences, USA. Meloxicam (Melo) was purchased from Boehringer Ingelheim, USA. 
AG, PGE-2 (PGE2) and PGF-2 alpha (PGF2α) standards, monoclonal β-actin antibody, 
secondary antibodies, Luria-Bertani broth (LB), and ampicillin were from Sigma 
Chemical Corp. USA. ETA was from Wyeth Lab, UK. The Dowew AG50-X8 column 
(Na+ form), nitrocellulose membranes, and all other Western blot reagents were from 
Bio-Rad Lab, USA. Filters were from Millipore Corp, USA. Primary cyclooxigenase 
(COX) antibodies were from Cayman Chemical. The HEK-Blue LPS Detection Kit was 
from InvivoGen, USA. The BCA Protein Assay Kit was from Pierce Biotechnology Inc, 
USA. All other chemicals were analytical grade.  
 
Animals 
To obtain timed pregnant females, male and virgin female Sprague-Dawley rats 
between 250 and 300 g of body weight (bwt) were acquired from the animal facility of 
the School of Veterinary, University of Buenos Aires. Mating was performed placing the 
female rats in the cages of the male rats from the same strain for several days. Day 1 of 
gestation was determined when sperm was observed in the vaginal smear. The animals 
received food and water ad libitum and were housed under controlled conditions of light 
(12-h light, 1-h dark) and temperature (23-25°C). This study was carried out in strict A
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accordance with the recommendations detailed in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. Protocols were approved for the 
Committee for the Care and Use of Laboratory Animals of the University of Buenos 
Aires (CICUAL, Permit Number 1209–10).  
 
Experimental Protocols  
Pregnant rats on day 15 of gestation (gd) were randomly divided into groups of at least 
three rats each. The Stx2 injury was induced as previously described (Burdet et al., 
2009). Briefly, Stx2-treated rats were injected (i.p.) with 0.5 ml of culture supernatant 
from recombinant E. coli containing 0.7 ng Stx2 and 50 pg LPS/g bwt. Control rats were 
inoculated with 0.5 ml of culture supernatant containing only LPS (50 pg LPS/g bwt). In 
separate experiments, control and Stx2-treated rats were injected (i.p.) with AG (100 
µg/g bwt) 24 h before and 4 h after toxins injection; Melo (2 µg/g bwt) simultaneously 
with the toxins and 12, 24 or 36 h later; ETA (100 µg/g bwt) 6 h before toxins; a 
combination of AG and Melo; or AG and ETA according the protocol previously 
described for each one. Rats from the different experimental groups were observed 
daily to evaluate delivery time and fetal status. Some of them were anesthetized and 
killed by cervical dislocation at different times after treatment. Placenta and decidua 
tissues were removed to evaluate PGs synthesis, NO synthase (NOS) activity, COX-1 
and COX-2 protein expression. Serum and amniotic fluid were obtained to measure 
TNF-α production. 
 
Determination of Prostaglandins  A
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Placenta and decidua were used to measures PGE2 and PGF2α levels as previously 
detailed (Ribeiro et al., 2005). Firstly, tissues were incubated for 1 h in Krebs-Ringer 
bicarbonate solution under a 5%-CO2 atmosphere at 37°C. Afterwards, medium was 
acidified and PGs were extracted twice with ethyl acetate. PGs concentration was 
determined by radioimmunoassay. Sensitivity was 5–10 pg per tube and values are 
expressed as pg PGs per mg of protein.  
 
Determination of NOS activity  
NOS enzyme activity in placenta was quantified from the conversion of L-[
14
C]arginine 
into L[14C]citrulline as described before (Burdet et al., 2010). In a few words, samples 
were weighed, homogenized and incubated with 10 µM L-[
14
C] arginine (0.3 µCi). After 
15 min, samples were centrifuged for 10 min at 10,000 g and applied to a Dowex AG50-
X8 column. L-[
14
C]citrulline was eluted and measured by liquid scintillation counting. 
Enzyme activity is reported as fmoles of L-[
14
C]citrulline per mg of protein per 15 min.  
 
TNF-α bioassay and immunoassay  
TNF bioactivity in serum and amniotic fluid samples was assayed employing the TNF-
sensitive cell line L929 (Shiau et al., 2001). In brief, 1 × 104 L929 cells per well were 
seeded into a 96well tissue culture plate and cultured in RPMI 1640 medium 
supplemented with 5 µg/ml streptomycin, 5 U/ml penicillin, and 10% fetal calf serum. 
The medium was replaced with 0.1 ml of medium alone, or with samples from Control or 
Stx2-treated rats. The L929 cells were grown in arrested-grown conditions (actinomycin 
D, 10 µg/ml). After 24 h incubation, the cells were washed with PBS and viability was A
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assayed by using the neutral red uptake technique (Goldstein et al., 2007). Bioactive 
TNF-α was expressed as percentage of L929 cell viability. Concentration of TNF-α was 
measured with the Biotrak rat TNF-α ELISA system according to the manufacturer’s 
instructions.the manufacturer’s instructions.  
 
Western Blot Analysis  
Tissues were processed according to the method explained before (Burdet et al., 2010). 
In short, placental and decidual tissues were fragmented and homogenized on ice in an 
appropriated buffer with protease inhibitors. Homogenates were pre-centrifuged at 
2,500 g for 10 min at 4º C and the collected supernatants were additionally centrifuged 
at 7,800 g for 10 min at 8º C. The supernatants were collected and stored at -70º C until 
western blotting was performed. Protein concentration was determined with the BCA 
Protein Assay Kit. One hundred micrograms of protein were loaded in each line. 
Samples were separated on 10 % (w/v) sodium dodecyl sulphate-polyacrylamide gel by 
electrophoresis and transferred to a PVDF membrane. The blots were incubated 48 h at 
4ºC with anti-COX-1 or anti-COX-2 rabbit polyclonal antibody diluted 1:250 in PBS. The 
membranes were then incubated for 1 h at room temperature with horseradish 
peroxidase-conjugated goat anti-rabbit Ig G antibody (1:3000). Proteins were detected 
through ECL detection system. To determine the uniformity of loading, protein blots 
were probed with a monoclonal anti-β-actin antibody (1:4000). Band intensities were 
measured using the Quantity One densitometry software package (Bio Rad Lab, USA). 
Protein bands were normalized to their respective β-actin bands.  
 
Statistics  A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
British Journal of Pharmacology © 2012 The British Pharmacological Society 
Statistical analysis was performed using the Graph Pad Prism Software (San Diego, 
CA, USA). Comparison between values of different groups was performed using one-
way ANOVA. Significance was determined using Tukey′s multiple comparison test for 
unequal replicated or Student′s t-test. Fisher exact test was used to compare the term 
and preterm delivery under different treatments. Statistical significance was set at p < 
0.05.  
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RESULTS 
Stx2 increases PGs levels in placenta and decidua  
Taking into account that during inflammation PGs are released simultaneously with NO, 
we examined the PGE2 and PGF2α expression in placenta and decidua from rats 
treated with Stx2 alone or in the presence of AG. In placenta, PGE2 showed an 
increase 12 h after Stx2 injection (p < 0.01, n = 18) while PGF2α remained constant. The 
treatment with AG plus Stx2 caused a greater increase in PGE2 (p < 0.001, n = 18) than 
the increase detected only with Stx2 and also caused an increase in PGF2α (p < 0.01, n 
= 18) (Figure 1A). In decidua, PGE2 decreased and PGF2α increased (p < 0.05, n = 18) 
in Stx2-treated rats while both PGs were similar to the controls after AG plus Stx2 
treatment (Figure 1B).  
 
Stx2 stimulates the COX-2 expression in placenta and decidua  
An increase in COX-2 protein expression was detected in placenta from rats treated 
with Stx2 alone or in the presence of AG (Figure 2A and C, p< 0.05, n= 6). The increase 
in COX-2 expression was also detected in decidua from Stx2-treated rats (p< 0.05, n= 
6) although the expression was similar to the controls under AG treatment (Figure 2B 
and D). None of the applied treatments changed the expression level of COX-1 in 
placental and decidual tissues of Stx2-treated rats (data no shown). These results 
suggest that changes in the PGs protein levels caused by Stx2 are mediated by COX-2 
and modulated by NO production.  
 
AG and Melo delay the preterm delivery induced by Stx2  A
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In order to determine whether the alterations in the PGs levels detected in placenta and 
decidua from Stx2-treated rats may be in part responsible for preterm delivery, Melo, a 
selective inhibitor of COX-2, was used. Table 1 shows that Melo did not prevent preterm 
delivery in Stx2-treated rats. One hundred percentage of the rats treated with Melo and 
Stx2 had premature delivery of dead fetuses while Control rats treated with Melo 
delivered normal live pups at term (Table 1, row 4 vs 3). Furthermore, we studied the 
ability of AG combined with Melo to prevent Stx2-induced preterm delivery. Previously, 
we have showed that AG administration did not prevent the premature delivery of dead 
fetuses (Table 1, row 6) (Burdet et al., 2010).  Instead, co-administration of AG and 
Melo delayed preterm delivery around 2 days in 50% of the rats, 3 days in 17 % of the 
rats and 4 days in 33 % of the rats but did not prevent the preterm delivery of dead 
fetuses (Table 1, row 8). These results suggest that both NO and PGs are involved in 
the Stx2 action on pregnant rats, although their blockade was not enough to reverse the 
Stx2-induced preterm delivery.  
 
Stx2 induces deregulation of serum TNF-α production  
TNF-α is one of the main cytokines that mediates the inflammatory response to Stx2 
and its deregulation, either systemic or locally, could be contributing to the changes 
observed during the development of pregnancy. To test this hypothesis, we determined 
the TNF-α levels in serum and amniotic fluid of Stx2-treated rats as well as its toxicity 
on TNF-sensitive cell line L929. 
An increase in TNF-α protein level in serum of Stx2-treated rats was maximal at 2 h 
after Stx2 injection, after which levels returned to normal at 6 h and 12 h (Figure 3A). 
Consequently, the toxic activity of TNF-α showed a reduction in the viability of L929 A
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cells to approximately 47% at 2 h after Stx2 injection (Figure 3B). However, the TNF-α 
level did not change in the amniotic fluid of pregnant rats treated with Stx2 (data no 
shown).  
The pretreatment with ETA was able to prevent the increase of TNF-α production in 
serum samples induced by Stx2 (Figure 4). ETA also prevented the significant increase 
in placental PGE2 (p < 0.001, n = 18) and decidual PGF2α (p < 0.001, n = 18) levels 
caused by Stx2 (Figure 5A and B). In contrast, no significant difference in placental 
NOS activity was found in rats treated with ETA + Stx2 compared with Stx2 alone. In 
both cases, a significant increase in NOS activity in placental tissues (p< 0.01, n = 6)   
was observed compared with the Control (Figure 6).  
 
ETA and AG prevent the preterm delivery induced by Stx2  
To determine whether the increase in TNF-α production and NOS activity triggers the 
Stx2 induced preterm delivery, we evaluated the action of ETA on the delivery time and 
fetal status of Stx2-treated rats. Administration of ETA 6 h before Stx2 injection 
prevented the preterm delivery by roughly 30% compared with their Controls (Table 1 
row 10 vs 9). Furthermore, we evaluated the combined action of AG and ETA in Stx2-
treated rats compared with Control rats. For the first time, we observed that the 
treatment with both inhibitors, AG plus ETA, significantly (p< 0.005, n = 10) prevented 
Stx2-induced preterm delivery by 70 % of the cases (Table 1, row 12). The pups of 
these rats were born alive and had normal development compared with their Controls 
(Table 1, row 11). These results suggest that the overproduction of TNF-α and NO is 
the major responsible of the preterm delivery of dead fetuses induced by Stx2.  A
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Discussion 
In this study, a significant increase in placental PGE2 and decidual PGF2α was found in 
Stx treated rats. Additionally, in both tissues COX-2 protein expression was stimulated 
by Stx2, although Melo, a specific inhibitor of COX-2, was unable to prevent placental 
toxicity and fetal mortality. Here, we found that production of PGs and expression of 
COX-2 protein were modulated by NOS activity in Stx2-treated rats. Thus, it is 
reasonable to infer that NO could elicit different effects on the progression of 
pregnancy, some directly related with its overproduction and others related with the 
regulation of PG production (Aisemberg et al., 2007). We reported before that AG 
prevented placental damages in Stx2-treated rats but did not prevent preterm delivery 
(Burdet et al., 2010). Here, the administration of AG together with Melo delayed preterm 
delivery but did not prevent it, which indicates that other factors are involved in the Stx2-
induced preterm delivery. It is well known that Stx may act in concert with LPS to elicit 
cellular dysfunction (Louise and Obrig, 1992). Stx is able to bind to Gb3 receptors 
expressed on the membrane of monocytes/macrophages and leads to cellular 
activation and secretion of cytokines such as TNF-α, IL-1β and IL-8 that increase the 
endothelial susceptibility to Stx (Ibarra and Palermo, 2010). Many studies conducted in 
human and experimental animals have established that a correct balance of cytokines 
at the maternal-fetal interface is an essential requirement for proper placental 
development and therefore reproductive success (Peltier, 2003; Gravett et al., 2007). In 
pregnant rats, administration of TNF-α produced placental injury and fetal death similar 
to the effects observed after LPS exposure (Silen et al., 1989). In this study, we showed 
that a significant increase in serum TNF-α observed 2 h after Stx2 treatment may be 
responsible for preterm delivery. Pregnancy loss was triggered by abnormal A
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inflammation as reported by other researchers (Grigsby et al., 2003; Renaud et al., 
2011). TNF-α in amniotic fluid was not detected suggesting that maternal more than 
fetal TNF-α exert its detrimental effects on pregnancy. Administration of ETA completely 
prevented the increase in serum TNF-α level caused by Stx2 as previously 
demonstrated in astrocytes treated with LPS and Stx1 (Landoni et al., 2010). Moreover, 
ETA prevented by 30% the preterm delivery caused by Stx2 and, although this is not 
significant, shows a tendency to the Stx2 effect prevention. Our results indicate that 
TNF-α may play a causal role in Stx2 pregnancy loss consistent with previous studies 
reported in human and animal models (Silver et al., 1994; Raghupathy et al., 2000). 
ETA also inhibited the induction of placental PGE2 and decidual PGF2α synthesis in 
Stx2-treated rats even in the presence of AG. These findings indicate that TNF-α 
stimulates PG production independent of NO production as it is described in the 
literature (Romero et al., 1988; Sato et al., 2003). ETA did not inhibit the increase of 
placental NOS activity caused by Stx2. Thus, it is reasonable to infer that Stx2-induced 
increase in NO production is not mediated by TNF-α. We assayed the combined action 
of AG and ETA on fetal status and delivery time in Stx2-treated rats. Co-administration 
of AG and ETA significantly prevented the preterm delivery caused by Stx2 by 
approximately 70% of the cases. The pups of these rats were similar in size and weight 
to those observed in the controls. These results indicate that the preterm delivery of 
dead fetuses induced by Stx2 is triggered by TNF-α and mediated by an increase in 
NOS production. Both placental PGE2 and decidual PGF2α increase secondarily to the 
increase in TNF-α and output of iNOS and contribute to the mechanisms that lead to the 
preterm delivery.  A
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In conclusion, the model presented in this study is relevant because it shows that Stx2 
increases TNF-α production, which renders the feto-maternal unit more susceptible to 
Stx2 through the stimulation of local PGs synthesis, which in turn may activate uterine 
contractions and cervical dilation. This proinflammatory environment could promote the 
contraction of the uterus and the expulsion of the fetuses. Additionally, Stx2 induces the 
overproduction of NO as a consequence of an increase in the levels of iNOS protein in 
placental tissues, which plays an important role in placental toxicity and fetal mortality. 
It is important to notice the fact that the administration of AG and ETA partially 
prevented preterm delivery of dead fetuses induced by Stx2. This suggests that they 
could be used in the future as therapeutic agents in this pathological consequence of 
HUS.  
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Figure legends 
Figure 1: Effects of Stx2 and AG on PGs production. Pregnant rats (gd 15) were 
treated with 50 pg LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) 
and killed 12 h post-treatment. Some animals were i.p. injected with AG (100 µg/g bwt) 
24 h before and 4 h after toxin injection. PGE2 and PGF2α levels were evaluated in 
placenta (A) and decidua (B) by RIA. Data corresponding to at least two separate 
experiments are shown. Values are expressed as the mean ± SEM (n = 18). *p < 0.05 
vs Control, **p < 0.01 vs Control, ***p < 0.001 vs Control, ap < 0.05 vs Stx2.  
 
Figure 2: Effect of Stx2 and AG on COX-2 protein expression. Pregnant rats were 
injected with 50 pg LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) 
and killed 12 h post-treatment. Some animals were i.p. injected with AG (100 µg/g bwt) 
24 h before and 4 h after toxin treatment. Placenta and deciduas were removed for 
Western blot analysis. To determine the uniformity of loading, blots were probed with a 
monoclonal anti-ß-actin antibody. Representative gel for COX-2 protein expression in 
placenta (A) and decidua (B) and the corresponding densitometry of the bands (C and 
D, respectively) are showed. Values correspond to the mean of 2 different pools of 6 
animals ± SEM. *p < 0.05 vs Control, #p < 0.05 vs Stx2 + AG.  
 
Figure 3: TNF-α production in pregnant rats. Pregnant rats were injected with 50 pg 
LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) and killed 0, 2, 6, 
12 and 24 h post-injection. Serum samples were used to determine amount of TNF-α by 
ELISA assay (A) and TNF-α cytotoxic activity by viability assay in L929 cells (B). Data A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
British Journal of Pharmacology © 2012 The British Pharmacological Society 
corresponding to at least two separate experiments are shown. Values are expressed 
as the mean ± SEM (n=6). *p < 0.05 vs Control.  
Figure 4: Effects of ETA on TNF-α production. Pregnant rats were injected with 50 
pg LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) and killed 2 h 
post-injection. Some animals were i.p. injected with ETA (100 µg/g bwt) 6 h before toxin 
treatment. Serum samples were used to determine amount of TNF-α by ELISA assay. 
Data corresponding to at least two separate experiments are shown. Values are 
expressed as the mean ± SEM (n= 4). *p< 0.05 vs Control, #p< 0.05 vs ETA + Stx2. 
 
Figure 5: Effect of ETA and AG on PGs production. Pregnant rats (gd 15) were 
injected with 50 pg LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) 
and killed12 h post-injection. Some animals were i.p. injected with ETA (100 µg/g) 6 h 
before toxin treatment. Others were treated with a combination of AG and ETA 
according the protocol described before for each one. PGE2 and PGF2α levels were 
evaluated in placenta (A) and decidua (B) by RIA. Data corresponding to at least two 
separate experiments are shown. Values are expressed as the mean ± SEM (n=18). 
ap< 0.05 vs Control, bp< 0.01 vs Control, cp< 0.001 vs Control, dp< 0.001 vs ETA 
control, ETA + Stx2 and AG + ETA + Stx2. 
 
Figure 6: Effect of ETA on NOS activity. Pregnant rats (gd 15) were injected with 50 
pg LPS/g bwt (Control) or with 0.7 ng Stx2 and 50 pg LPS/g bwt (Stx2) and killed12 h 
post-injection. Some animals were treated with ETA (100 µg/g) 6 h before toxin 
treatment. NOS activity in placenta was quantified by measuring the conversion of L-
[
14
C] arginine into L-[
14
C] citrulline. Data corresponding to at least two separate A
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experiments are shown. Values are expressed as the mean ± SEM (n=6). **p< 0.01 vs 
Control. 
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Table 1: Effect of Melo, AG and ETA on delivery time and pups status  
  Preterm delivery (%)  Term delivery 
(%) 
Live/dead 
pups (%) 
Treatment *N gd 16-17 gd 18 gd 19 gd 20 gd 21  gd 22 gd 23  
Control 6 0 0 0 0 0  0 100 100/0 
Stx2 8 100 0 0 0 0  0 0a 0/100 
†Melo Control 6 0 0 0 0 0  0 100 100/0 
†Melo + Stx2 8 100 0 0 0 0  0 0b 0/100 
#AG Control 6 0 0 0 0 0  0 100 100/0 
#AG + Stx2 6 100 0 0 0 0  0 0c 0/100 
#AG+ †Melo Control 6 0 0 0 0 0  0 100 100/0 
#AG+ †Melo + Stx2 6 0 0 50 17 33  0 0d 0/100 
¥ETA Control 3 0 0 0 0 0  0 100 100/0 
¥ETA + Stx2 10 30 30 0 0 10  0 30 30/70 
#AG + ¥ETA Control 3 0 0 0 0 0  0 100 100/0 
#AG + ¥ETA + Stx2 10 0 0 0 0 30  0 70e 70/30 
†Melo: 2 µg/g bwt, #AG: 100 µg/g bwt, ¥ETA: 100 µg/g bwt, *N= number of rats. 
ap<0.005 vs Control; bp<0.005 vs Melo Control; cp<0.005 vs AG Control; dp<0.005 vs AG + Melo Control; 
ep<0.005 vs Stx2. a,b,c,d,eCalculated by Fisher exact test. 
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